Phase I-II study of weekly nab (nanoparticle albumin-bound)-paclitaxel (nab-paclitaxel) in combination with liposomal encapsulated doxorubicin (LDox) in patients with HER2 negative metastatic breast cancer (ABRAMYO STUDY)

Trial Profile

Phase I-II study of weekly nab (nanoparticle albumin-bound)-paclitaxel (nab-paclitaxel) in combination with liposomal encapsulated doxorubicin (LDox) in patients with HER2 negative metastatic breast cancer (ABRAMYO STUDY)

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 31 Jul 2014

At a glance

  • Drugs Paclitaxel (Primary) ; Doxorubicin liposomal
  • Indications Breast cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms ABRAMYO
  • Most Recent Events

    • 31 Jul 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top